BeOne Medicines Ltd. American Depositary Shares (ONC)
Stock · NASDAQ · Health Care
$369.27as of 10/16/2026
Price chart
Active signals
ONC Signal Track Record
How signals performed across all stocks →What ONC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +2.9% | 58% | September 23, 2026 |
| Bollinger Band Breakout | 27 | +2.9% | 59% | August 7, 2026 |
| Bollinger Band Breakdown | 17 | -0.1% | 47% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +12.5% | 78% | July 31, 2026 |
| Any 20-session window (baseline) | +1.1% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 12,000
- Website
- beonemedicines.com/
Fundamentals
- 1-day range
- $356.61$375.64
- Market cap
- $36.67B
- P/E (trailing)
- 61.27
- P/E (forward)
- 36.48
- EPS (trailing)
- $2.80
- Dividend yield
- —
- Beta
- 1.47
- Avg. volume
- 386.7K
How BeOne Medicines Ltd. American Depositary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
27 analyst ratings
BeOne Medicines Ltd. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
- TEVATeva Pharmaceutical Industries Limited American Depositary Shares$41.5▲ 0.95%Market cap $40.56BP/E 68.57$6,207$12,990
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
| TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $40.56B | 68.57 | $41.5 | ▲ 0.95% | $6,207$12,990 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459Benzinga · 10/8/2026
- Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420Benzinga · 10/7/2026
- Biotech Leader BeOne Medicines Poised To Hit Early Buy PointsYahoo · 10/1/2026
- JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445Benzinga · 10/1/2026
- BeiGene Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · 9/17/2026
- Tracking Baker Brothers' Portfolio: Q2 2026 UpdateSeekingAlpha · 9/16/2026
- BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
- Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimensbenzinga · 8/25/2026
Insider Activity
Insider Actions →- Chan Henry Lee · September 30, 2026 · Sale1.1K @ $375
- Xiaodong Wang · September 8, 2026 · Option Exercise403.4K
- Xiaodong Wang · September 8, 2026 · Sale6.3K @ $351.25
- Xiaodong Wang · September 8, 2026 · Sale6.6K @ $350.27
- Xiaodong Wang · September 8, 2026 · Sale10.7K @ $349.28
- Xiaodong Wang · September 8, 2026 · Sale7.5K @ $348.31
- Xiaodong Wang · September 8, 2026 · Option Exercise31.0K @ $36.9
- Xiaodong Wang · September 8, 2026 · Sale1.7K @ $348.01
- Xiaodong Wang · September 8, 2026 · Sale1.5K @ $347.39
- Xiaodong Wang · September 8, 2026 · Sale2.8K @ $346.16
- Xiaodong Wang · September 8, 2026 · Sale1.2K @ $345.38
- Titus B. Ball · September 1, 2026 · Sale132 @ $355.86
- Xiaobin Wu · August 25, 2026 · Sale280 @ $380
- John Oyler · August 12, 2026 · Sale14.1K @ $359.12
- John Oyler · August 12, 2026 · Sale20.9K @ $358.41
Institutional Ownership
March 31, 2026
- Total shares held
- 3.00M
- Total value held
- $2.53M
- Institutional holders
- 56
- Unknown8.80M
- Unknown4.98M
- Unknown4.16M
- Unknown3.69M
- Unknown1.62M
- Unknown1.05M
- Unknown1.03M
- Unknown862.6K
- Unknown715.8K
- Unknown657.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List
BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.